Subgroup | Â | Pooled OS | Heterogeneity | ||
---|---|---|---|---|---|
HR[95% CI] | p | I2 | p | ||
Combination therapeutic agents | Chemotherapy | 0.71[0.61, 0.84] | 0.000 | 0% | 0.660 |
PARP inhibitors | 0.86[0.50, 1.47] | 0.581 | - | - | |
Trial phase | phase II | 0.65[0.54, 0.79] | 0.000 | 0% | 0.933 |
phase III | 0.85[0.66, 1.09] | 0.196 | - | - | |
Region | non-Asia | 0.74[0.62, 0.88] | 0.001 | 5.4% | 0.376 |
Asia | 0.66[0.47, 0.94] | 0.02 | 0% | 0.997 | |
ECOG | 0–2 | 0.72[0.61, 0.85] | 0.000 | 0% | 0.539 |
0–4 | 0.76[0.52, 1.13] | 0.173 | 0% | 0.529 | |
Primary tumor site | OC, FTC, PC | 0.73[0.62, 0.86] | 0.000 | 0% | 0.492 |
OC | 0.66[0.41,1.07] | 0.094 | 0% | 0.935 | |
Publication year | within 5 years | 0.66[0.53, 0.81] | 0.000 | 0% | 0.880 |
5 years ago | 0.81[0.65, 1.02] | 0.075 | 1.6% | 0.313 |